[
  {
    "ts": null,
    "headline": "Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?",
    "summary": "Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious liver-related adverse event in a patient dosed in late September 2025. The therapy, developed in collaboration with Regeneron and holding Orphan Drug and RMAT designations, is now under further safety evaluation as the company consults with regulatory authorities and medical experts. We'll examine how...",
    "url": "https://finnhub.io/api/news?id=72a3bb09b95a1ab72be77f5185dd42a292d59cce7ab3d3f135717b50475c4f36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761685758,
      "headline": "Intellia Therapeutics (NTLA) Is Down 45.2% After Pausing Key Nex-z Trials Over Safety Issue – Has The Bull Case Changed?",
      "id": 137244040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious liver-related adverse event in a patient dosed in late September 2025. The therapy, developed in collaboration with Regeneron and holding Orphan Drug and RMAT designations, is now under further safety evaluation as the company consults with regulatory authorities and medical experts. We'll examine how...",
      "url": "https://finnhub.io/api/news?id=72a3bb09b95a1ab72be77f5185dd42a292d59cce7ab3d3f135717b50475c4f36"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Break Records as Fed Set to Cut While Gains Accrue From Earnings, Corporate Actions",
    "summary": "US equity indexes rose on Tuesday, with the mainstream benchmark gauges breaking records ahead of th",
    "url": "https://finnhub.io/api/news?id=0262ee6ded76684056930fb27918412f1cfad2257b51e74ac1f2ec67a81c5e06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761684727,
      "headline": "US Equity Indexes Break Records as Fed Set to Cut While Gains Accrue From Earnings, Corporate Actions",
      "id": 137243121,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes rose on Tuesday, with the mainstream benchmark gauges breaking records ahead of th",
      "url": "https://finnhub.io/api/news?id=0262ee6ded76684056930fb27918412f1cfad2257b51e74ac1f2ec67a81c5e06"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Markets End Higher Amid Expectations of Another Fed Rate Cut",
    "summary": "US equity indexes closed higher on Tuesday, hitting record highs during the day ahead of the Fed's e",
    "url": "https://finnhub.io/api/news?id=d01a55cb5f8571c1891b2bf96e50554bb86cc229a49b4c1b417b0e3d58b68b98",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761681998,
      "headline": "US Equity Markets End Higher Amid Expectations of Another Fed Rate Cut",
      "id": 137243127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes closed higher on Tuesday, hitting record highs during the day ahead of the Fed's e",
      "url": "https://finnhub.io/api/news?id=d01a55cb5f8571c1891b2bf96e50554bb86cc229a49b4c1b417b0e3d58b68b98"
    }
  },
  {
    "ts": null,
    "headline": "REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase",
    "summary": "Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.",
    "url": "https://finnhub.io/api/news?id=66c6b2ecb4f84166a15ba307d51ccc5197a2e4ee18e8fcb9b93917ea94a83419",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761678180,
      "headline": "REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase",
      "id": 137244043,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.",
      "url": "https://finnhub.io/api/news?id=66c6b2ecb4f84166a15ba307d51ccc5197a2e4ee18e8fcb9b93917ea94a83419"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Scale New Highs Amid Strong Earnings, Corporate Actions",
    "summary": "US equity indexes rose after midday on Tuesday, breaking records amid gains from quarterly earnings",
    "url": "https://finnhub.io/api/news?id=194b19796ed6463b9cc40c2abc4bcc8de2084c02db90bdd27a0156c8afa31e47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761674119,
      "headline": "US Equity Indexes Scale New Highs Amid Strong Earnings, Corporate Actions",
      "id": 137243971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes rose after midday on Tuesday, breaking records amid gains from quarterly earnings",
      "url": "https://finnhub.io/api/news?id=194b19796ed6463b9cc40c2abc4bcc8de2084c02db90bdd27a0156c8afa31e47"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Retreat Tuesday Afternoon",
    "summary": "Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the",
    "url": "https://finnhub.io/api/news?id=f005ba03e0e942a4b15e408be475a4ca0b43422d2dca817ce61eb44892b25fa8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761673519,
      "headline": "Sector Update: Health Care Stocks Retreat Tuesday Afternoon",
      "id": 137242484,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the",
      "url": "https://finnhub.io/api/news?id=f005ba03e0e942a4b15e408be475a4ca0b43422d2dca817ce61eb44892b25fa8"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts",
    "summary": "Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts",
    "url": "https://finnhub.io/api/news?id=e7042d504561ec9b1480d3363554607d5e118eab023cf80438ed45cba9646c17",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761672233,
      "headline": "Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts",
      "id": 137255792,
      "image": "",
      "related": "REGN",
      "source": "DowJones",
      "summary": "Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts",
      "url": "https://finnhub.io/api/news?id=e7042d504561ec9b1480d3363554607d5e118eab023cf80438ed45cba9646c17"
    }
  },
  {
    "ts": null,
    "headline": "Why Are Regeneron (REGN) Shares Soaring Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit.",
    "url": "https://finnhub.io/api/news?id=9e02be6d864cfb633b343bde72f318c2031e0d679ed5b15a5a1c6a83725e2419",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667893,
      "headline": "Why Are Regeneron (REGN) Shares Soaring Today",
      "id": 137244047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit.",
      "url": "https://finnhub.io/api/news?id=9e02be6d864cfb633b343bde72f318c2031e0d679ed5b15a5a1c6a83725e2419"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia investing $1B in Nokia, Trump admin. inks nuclear deal",
    "summary": "Yahoo Finance anchor Julie Hyman tracks Tuesday's top moving stocks and biggest market stories in this Market Minute. Nvidia (NVDA) is investing $1 billion in Nokia (NOK) and providing chips to the company for its 5G software. Westinghouse Electric, owned by Cameco (CCJ) and Brookfield (BAM), is partnering with the Trump administration to build nuclear reactors. Regeneron (REGN) stock is rising after the company's third quarter earnings results topped Wall Street's estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=f13dce15708b858370b1e45873b7e6fc3f4c250bb717c88f034668da30c27dbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667842,
      "headline": "Nvidia investing $1B in Nokia, Trump admin. inks nuclear deal",
      "id": 137244049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Yahoo Finance anchor Julie Hyman tracks Tuesday's top moving stocks and biggest market stories in this Market Minute. Nvidia (NVDA) is investing $1 billion in Nokia (NOK) and providing chips to the company for its 5G software. Westinghouse Electric, owned by Cameco (CCJ) and Brookfield (BAM), is partnering with the Trump administration to build nuclear reactors. Regeneron (REGN) stock is rising after the company's third quarter earnings results topped Wall Street's estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=f13dce15708b858370b1e45873b7e6fc3f4c250bb717c88f034668da30c27dbd"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-28. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
    "url": "https://finnhub.io/api/news?id=582f91e7e41431dc01753719e8cc59ccc3955b230131ee32fd4c536e0de2af21",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761659090,
      "headline": "Regeneron Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137239987,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "2025-10-28. The following slide deck was published by Regeneron Pharmaceuticals, Inc.",
      "url": "https://finnhub.io/api/news?id=582f91e7e41431dc01753719e8cc59ccc3955b230131ee32fd4c536e0de2af21"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsRyan Crowe - Senior Vice President of...",
    "url": "https://finnhub.io/api/news?id=c0761223111a526b9d041dc570b6684dbcaf22c303fd5f757297b31023796b1c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761658314,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript",
      "id": 137239963,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsRyan Crowe - Senior Vice President of...",
      "url": "https://finnhub.io/api/news?id=c0761223111a526b9d041dc570b6684dbcaf22c303fd5f757297b31023796b1c"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics",
    "summary": "Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=6f548b95f8adfc4160b813b00c9e6cd457f9c442e40c58109bc7deab7c63e513",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761658209,
      "headline": "Compared to Estimates, Regeneron (REGN) Q3 Earnings: A Look at Key Metrics",
      "id": 137244050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=6f548b95f8adfc4160b813b00c9e6cd457f9c442e40c58109bc7deab7c63e513"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (NASDAQ:REGN) Surprises With Strong Q3",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=84d3eb6a9399df6446470d35a1357a748d90b49e26a6fb1813b1597fa9ed7bf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761652683,
      "headline": "Regeneron (NASDAQ:REGN) Surprises With Strong Q3",
      "id": 137238135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=84d3eb6a9399df6446470d35a1357a748d90b49e26a6fb1813b1597fa9ed7bf5"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=21dbad977791a462eefaaebc9fa00cf6e209bc0dadb20c71932959338f5cb6d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761651603,
      "headline": "Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates",
      "id": 137238136,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=21dbad977791a462eefaaebc9fa00cf6e209bc0dadb20c71932959338f5cb6d2"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron earnings beat estimates amid strong anti-inflammatory drug demand",
    "summary": "Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to soaring demand for its anti-inflammatory drug.",
    "url": "https://finnhub.io/api/news?id=384cc2b88d4d1afe4eded8736712b87765e39a3e2ee35f89d451953eeafb8842",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761649608,
      "headline": "Regeneron earnings beat estimates amid strong anti-inflammatory drug demand",
      "id": 137238137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to soaring demand for its anti-inflammatory drug.",
      "url": "https://finnhub.io/api/news?id=384cc2b88d4d1afe4eded8736712b87765e39a3e2ee35f89d451953eeafb8842"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Q3 Earnings Snapshot",
    "summary": "TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Tuesday reported third-quarter net income of $1.46 billion. On a per-share basis, the Tarrytown, New York-based company said it had net income of $13.62.",
    "url": "https://finnhub.io/api/news?id=051014fadec8c8b41037d2946ffacd60bb08443f4412a97588529f849c90d425",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761648058,
      "headline": "Regeneron: Q3 Earnings Snapshot",
      "id": 137238138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Tuesday reported third-quarter net income of $1.46 billion. On a per-share basis, the Tarrytown, New York-based company said it had net income of $13.62.",
      "url": "https://finnhub.io/api/news?id=051014fadec8c8b41037d2946ffacd60bb08443f4412a97588529f849c90d425"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Reports Third Quarter 2025 Financial and Operating Results",
    "summary": "Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant",
    "url": "https://finnhub.io/api/news?id=a1bad2a21417e96b090107c41b93b872a52c6cb83620bd85eee17919ef82ceab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761647400,
      "headline": "Regeneron Reports Third Quarter 2025 Financial and Operating Results",
      "id": 137238139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant",
      "url": "https://finnhub.io/api/news?id=a1bad2a21417e96b090107c41b93b872a52c6cb83620bd85eee17919ef82ceab"
    }
  }
]